{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:21:51Z","timestamp":1781112111825,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"European Commission Seventh Framework Programme","doi-asserted-by":"publisher","award":["259,744"],"award-info":[{"award-number":["259,744"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clinre.2015.06.016","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T09:18:31Z","timestamp":1437383911000},"page":"S80-S85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S1","title":["New molecular therapies for hepatocellular carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"S.","family":"Torrecilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Llovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2015.06.016_bib0250","first-page":"117","article-title":"Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Naghavi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2015.06.016_bib0255","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0260","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0265","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2015.06.016_bib0270","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0275","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0280","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0285","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2015.06.016_bib0290","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0295","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2015.06.016_bib0300","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0305","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.26221","article-title":"Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma","volume":"57","author":"Camm\u00e0","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0310","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0315","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0325","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clinre.2015.06.016_bib0330","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0335","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2015.06.016_bib0340","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.20636","article-title":"Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort","volume":"41","author":"Marrero","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0345","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clinre.2015.06.016_bib0495","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0355","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0360","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-12-0151","article-title":"Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib","volume":"18","author":"Villanueva","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2015.06.016_bib0365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/sim.4780130506","article-title":"New designs for the selection of treatments to be tested in randomized clinical trials","volume":"13","author":"Simon","year":"1994","journal-title":"Stat Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0370","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u00a0\u2013\u00a0the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clinre.2015.06.016_bib0375","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2015.06.016_bib0380","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clinre.2015.06.016_bib0385","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinre.2015.06.016_bib0390","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0395","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0400","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","article-title":"Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC","volume":"130","author":"Calvisi","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0405","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1593\/neo.13812","article-title":"Allosteric MEK1\/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma","volume":"15","author":"Schmieder","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.clinre.2015.06.016_bib0410","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1158\/1078-0432.CCR-13-3445","article-title":"A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma","volume":"20","author":"Lim","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.clinre.2015.06.016_bib0500","article-title":"A phase 2 study of a novel transforming growth factor-beta receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma. 2014. Gastrointestinal Cancers Symposium","volume":"32","author":"Faivre","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clinre.2015.06.016_bib0425","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0430","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1158\/1538-7445.AM2012-3858","article-title":"Abstract 3858: gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro","volume":"72","author":"Finn","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinre.2015.06.016_bib0435","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clinre.2015.06.016_bib0440","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-LB-324","article-title":"Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma","volume":"74","author":"Hagel","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinre.2015.06.016_bib0445","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinre.2015.06.016_bib0450","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0455","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0460","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hep.22626","article-title":"A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma","volume":"49","author":"Palmer","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2015.06.016_bib0465","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0470","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0475","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMoa0901282","article-title":"MicroRNA expression, survival, and response to interferon in liver cancer","volume":"361","author":"Ji","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2015.06.016_bib0480","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI27236","article-title":"Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype","volume":"116","author":"Kaposi-Novak","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinre.2015.06.016_bib0485","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinre.2015.06.016_bib0490","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740115001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740115001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:22:48Z","timestamp":1761895368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740115001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":49,"alternative-id":["S2210740115001515"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2015.06.016","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New molecular therapies for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2015.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}